Though the use of ESAs have negative consequences (e.g., increased blood pressure and thromboembolism), the risks of Epo therapy should be weighed against the potential beneficial effects of improving anemia, quality of life, and neurocognitive performance and decreasing the impact of ischemia in the brain, heart, and other organs. Here, EPO is linked to ischemia.